{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-007042","form_type":"8-K","ticker":"VTAK","cik":"0001716621","company_name":"Catheter Precision, Inc.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.195313+00:00","generated_at":"2026-06-14T18:20:37.860230+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ra Medical delays Q1 10-Q filing; cites acquisition accounting issues, goodwill write-off expected","bullets":["Company will not file Q1 2023 10-Q by deadline; no exact filing date projected.","Delay due to auditor review of Catheter Precision acquisition accounting, including Series X preferred stock valuation.","Projects Q1 2023 revenue of ~$85,000; expects all or substantially all goodwill to be written off.","Decline in RMED stock price since Jan 9 acquisition date caused decline in value of acquired assets under review."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-007042","json":"https://secwatch.observer/filing/0001654954-23-007042.json","markdown":"https://secwatch.observer/filing/0001654954-23-007042.md","text":"https://secwatch.observer/filing/0001654954-23-007042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423007042/0001654954-23-007042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423007042/rmed_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:20:37.860230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"606090ca7e9e2bc3ff2ee1477b309ec6baf922c1","claim":"Catheter Precision, Inc. reported the quarter ended March 31, 2023 results: revenue approximately $85,000.","evidence_excerpt":"The Company continues to project revenues for the quarter ended March 31, 2023 of approximately $85,000, and also projects that all or substantially all of its goodwill will be written off as a result of the finalization of the purchase price allocation in connection with the Company’s merger with Catheter Precision, Inc.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423007042/0001654954-23-007042-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"approximately $85,000"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}